



WEO

The voice of world  
endoscopy

# Colonoscopy Prioritization

Revital Kariv, MD

Maccabi Health Care Services- Health Division

Tel Aviv Sourasky Medical Center

Tel Aviv University



# Statement- No disclosures



# Relevance/Rationale: Colonoscopy Uptake Increases Worldwide

- Increased awareness for CRC screening and high risk populations
- Younger screening onset
- Wider availability
- Better tolerance

## **Real-World National Colonoscopy Volume in Korea: A Nationwide Population-Based Study over 12 Years**

Jae Myung Cha<sup>1</sup>, Min Seob Kwak<sup>1</sup>, Hyun-Soo Kim<sup>2</sup>, Su Young Kim<sup>2</sup>, Sohee Park<sup>3</sup>, Geun U Park<sup>4</sup>, Jung Kuk Lee<sup>5</sup>, Soo Jin Kim<sup>6</sup>, Hun Hee Lee<sup>6</sup>, Joo Sung Kim<sup>7</sup>, and Won Ho Kim<sup>8</sup>, for the Big Data Research Group of the Korean Society of Gastroenterology

*Gut and Liver, Vol. 14, No. 3, May 2020, pp. 338-346*





**Limited  
Resources**

**Slots  
Endoscopists  
Consultations**

**COVID-19**





# The Pandemic highlighted the Need For Prioritization

## Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study

Amit Sud\*, Bethany Torr\*, Michael E Jones, John Broggio, Stephen Scott, Chey Loveday, Alice Garrett, Firza Gronthoud, David L Nicol, Shaman Jhanji, Stephen A Boyce, Matthew Williams, Elio Riboli, David C Muller, Emma Kipps, James Larkin, Neal Navani, Charles Swanton, Georgios Lyratzopoulos, Ethna McFerran, Mark Lawler, Richard Houlston, Clare Turnbull

Lancet Oncol 2020; 21: 1035–44

**Interpretation** Prompt provision of additional capacity to address the backlog of diagnostics will minimise deaths as a result of diagnostic delays that could add to those predicted due to expected presentational delays. Prioritisation of patient groups for whom delay would result in most life-years lost warrants consideration as an option for mitigating the aggregate burden of mortality in patients with cancer.

Prioritisation by FIT to mitigate the impact of delays in the 2-week wait colorectal cancer referral pathway during the COVID-19 pandemic: a UK modelling study

*Gut* 2021;**70**:1053–1060.

FIT based prioritization modelling




# FIT threshold adjustment

## Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels

Esther Toes-Zoutendijk,<sup>1</sup> Monique E. van Leerdam,<sup>2</sup> Evelien Dekker,<sup>3</sup> Frank van Hees,<sup>1</sup> Corine Penning,<sup>1</sup> Iris Nagtegaal,<sup>4</sup> Miriam P. van der Meulen,<sup>1</sup> Anneke J. van Vuuren,<sup>5</sup> Ernst J. Kuipers,<sup>6</sup> Johannes M. G. Bonfrer,<sup>6</sup> Katharina Biermann,<sup>7</sup> Maarten G. J. Thomeer,<sup>8</sup> Harriët van Veldhuizen,<sup>9</sup> Sonja Kroep,<sup>1</sup> Marjolijn van Ballegooijen,<sup>1</sup> Gerrit A. Meijer,<sup>10</sup> Harry J. de Koning,<sup>1</sup> Manon C. W. Spaander,<sup>2</sup> and Iris Lansdorp-Vogelaar,<sup>1</sup> on behalf of the Dutch National Colorectal Cancer Screening Working Group

Gastroenterology 2017;152:767-775




## Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study

J Med Screen


2022, Vol. 29(2) 72-83

Cancer Global Modelling Consortium (CCGMC) working group





# Populations for Colonoscopy Uptake



# Does One FITs all?

Global Cancer  
screening  
programs

Personalized  
Cancer  
Prediction

One FITs all

Cost effective tests  
trafficking

Suits large health  
systems

Efficacy, motivation

Familiar

Safety

Easier, simple

Targeted screening





# Literature Review- FIT, ColonFlag

## The Value of Quantitative Faecal Immunochemical Testing as a Prioritisation Tool for the Endoscopic Investigation of Patients With Iron Deficiency

William Clackett, Stephen T. Barclay, Adrian J. Stanley and Aidan Cahill\*

ORIGINAL RESEARCH  
published: 22 July 2021

## Priority stratification for colonoscopy based on two-sample faecal immunochemical test screening: results from a cross-sectional study at an endoscopy clinic in Japan

Toyoshima O, et al. *BMJ Open* 2021;**11**:e046055.

**bjh** research paper

## Potential roles of artificial intelligence learning and faecal immunochemical testing for prioritisation of colonoscopy in anaemia

*British Journal of Haematology*, 2019, **185**, 311–316




# Risk Prediction Scores

ORIGINAL ARTICLE

Comparison of prognostic models to predict the occurrence of colorectal cancer in asymptomatic individuals: a systematic literature review and external validation in the EPIC and UK Biobank prospective cohort studies

Smith T, et al. *Gut* 2019;

The C-statistics of the models were largely similar between validation cohorts with the highest values achieved being 0.70 (95% CI 0.68 to 0.72) in the UK Biobank and 0.71 (95% CI 0.67 to 0.74) in EPIC.



| Author                              | Sex  | Outcome | Demographic characteristics |     |     | Anthropometry |        | Family history of Cancer | Medical history |          |                       | Medication use |                   |     | Lifestyle factors |       |                   | Diet    |         |                   |     |     |
|-------------------------------------|------|---------|-----------------------------|-----|-----|---------------|--------|--------------------------|-----------------|----------|-----------------------|----------------|-------------------|-----|-------------------|-------|-------------------|---------|---------|-------------------|-----|-----|
|                                     |      |         | Sex                         | Age | Eth | Edu           | Height |                          | BMI             | Diabetes | Screen/endo/<br>polyp | IBD            | Menopausal status | HRT | OC                | NSAID | Physical activity | Smoking | Alcohol | Red meat/<br>meat | Veg | Vit |
| Colditz <sup>23</sup>               | M    | C       |                             | ●   |     |               | ●      | ●                        |                 |          | ●                     |                |                   |     |                   | ●     | ●                 |         | ●       | ●                 | ●   |     |
|                                     | F    | C       |                             | ●   |     |               | ●      | ●                        |                 |          | ●                     |                | ●                 |     | ●                 | ●     |                   | ●       | ●       | ●                 | ●   |     |
| Driver <sup>24</sup>                | M    | CRC     |                             | ●   |     |               |        | ●                        |                 |          |                       |                |                   |     |                   |       |                   | ●       |         |                   |     |     |
|                                     | M    | CRC     |                             | ●   |     |               |        | ●                        |                 |          | ●                     |                |                   |     |                   |       |                   |         |         |                   | ●   |     |
| Freedman <sup>7</sup>               | F    | CRC     |                             | ●   |     |               |        | ●                        |                 |          | ●                     |                |                   |     |                   | ●     | ●                 |         |         |                   | ●   |     |
|                                     | M    | CRC     |                             | ●   |     |               |        | ●                        |                 |          |                       |                | ○ α               | ○ α |                   | ●     | ●                 |         |         |                   | ●   |     |
| Ma <sup>9</sup>                     | M    | CRC     |                             | ●   |     |               |        | ●                        |                 |          |                       |                |                   |     |                   | ●     | ●                 |         | ●       |                   |     |     |
|                                     | M    | C       |                             | ●   |     |               |        | ●                        |                 |          |                       |                |                   |     |                   | ●     | ●                 |         | ●       |                   |     |     |
|                                     | M    | R       |                             | ●   |     |               |        |                          |                 |          |                       |                |                   |     |                   | ●     |                   | ●       |         |                   |     |     |
| Shin <sup>25</sup>                  | M    | R C     |                             | ●   |     |               |        | ●                        | ●               |          |                       |                |                   |     |                   |       |                   | ●       |         | ●                 |     |     |
|                                     | F    | R       |                             | ●   |     |               | ●      |                          |                 |          |                       |                |                   |     |                   |       |                   | ●       | ●       |                   |     |     |
| Steffen <sup>10</sup>               | Both | CRC     | ●                           | ●   |     |               |        | ●                        |                 |          | ●                     |                |                   |     |                   |       |                   | ●       | ●       | ●                 |     |     |
|                                     | Both | C       | ●                           | ●   |     |               |        | ●                        |                 |          | ●                     |                |                   |     |                   |       |                   | ●       | ●       | ●                 |     |     |
|                                     | Both | R       | ●                           | ●   |     |               |        | ●                        |                 |          | ●                     |                |                   |     |                   |       |                   | ●       | ●       | ●                 |     |     |
| Taylor <sup>8</sup>                 | Both | CRC     |                             | ●   |     |               |        |                          | ●               |          |                       |                |                   |     |                   |       |                   |         |         |                   |     |     |
|                                     | M    | CRC     |                             | ●   | ●   | ●             |        | ●                        | ●               | ●        | ●                     |                |                   |     |                   | ●     | ●                 | ●       | ●       |                   | ●   |     |
| Wells <sup>26</sup>                 | F    | CRC     |                             | ●   | ●   |               |        | ●                        | ●               | ●        | ●                     |                |                   |     |                   | ●     | ●                 | ●       | ●       |                   | ●   |     |
|                                     |      |         |                             |     |     |               |        |                          |                 |          |                       |                | ○ μ               | ○ μ |                   | ●     | ●                 | ●       | ●       |                   | ●   |     |
| Variable availability in EPIC       |      |         | ■                           | ■   |     | □             | ■      | ■                        | □               | ■        | □                     |                | na                | □   | □                 | □     | ■                 | ■       | ■       | □                 | □   | □   |
| Variable availability in UK Biobank |      |         | ■                           | ■   | ■   | □             | ■      | ■                        | □               | ■        | ■                     | ■              | na                | □   | □                 | □     | □                 | ■       | ■       | □                 | □   | ■   |

Sassano et al. *BMC Cancer* (2022) 22:65  
<https://doi.org/10.1186/s12885-021-09143-2>

BMC Cancer

RESEARCH

Open Access

## Polygenic risk prediction models for colorectal cancer: a systematic review

Michele Sassano<sup>1†</sup>, Marco Mariani<sup>1†</sup>, Gianluigi Quaranta<sup>1,2</sup>, Roberta Pastorino<sup>2\*</sup> and Stefania Boccia<sup>1,2</sup>



# Colonoscopy Prioritization Considerations

---

**Tool**      **Performance**

---

**Threshold**

---

**Parameters**

**Adjusting for  
screen benefit-**

**Age, BG**

---





---

**Implementation**

**Target Population**

---

**Upon referral/Initiated**

---

**Recommendations for clinicians**

---

**Workflow**

---





# MHS Initiative for Prioritization

- MHS- 2nd largest HMO in Israel, 2.5 million
- National screening program includes colonoscopy for average risk

- **MHS screening status**


- 68.4% are screened, 5% FIT, 47% performed colonoscopy

for the unscreened upon CBC uptake

Colonoscopy Volume is to be Limited



# ColonFlag – Machine Learning Risk Model for CRC



Flag individuals not up-to-date with Colorectal Cancer (CRC) screening guidelines at high risk of harboring Colorectal Cancer using only complete blood count (CBC) test results, age and sex.



Well validated:

5 Retrospective Peer Reviewed Validation Studies  
2 Peer Reviewed Real Use Observational Studies

Property of Medial EarlySign. Confidential. Do not reproduce or distribute.

2



British Journal of Cancer (2017) 116, 944–950 |

PLOS ONE | February 9, 2017

Clin Cancer Inform. © 2018 by American Society of Clinical Oncology




# Real World Evidence, Geisinger(\*)

- 25,610 patients not-complying with screening, with CBC taken during study period(\*\*) were analyzed
- Out of these, 706 patients were flagged (2.8%), an average of 11.2 patients per week
- Flagged patient list weekly transferred to care management
- 68.1% of flagged patients were subsequently scheduled for colonoscopies
- Of these flagged patients who underwent colonoscopy,
  - Approximately 70% had a significant finding
  - 8% PPV for CRC (1:12)
  - 51% detected with Adenoma / Polyp (1:2)


(\*) Published in: Collaboration to Improve Colorectal Cancer Screening using Machine Learning, *NEJM Catalyst Innovations in Care Delivery: Vol. 3 Issue 4 | April 2022* ([link](#))  
(\*\*) LGI-Flag installed on site, results during a 63-week period (May 14, 2019 - July 28, 2020)

Property of Medial EarlySign. Confidential. Do not reproduce or distribute.

3



Colonoscopy Results, LGI-Flagged Patients, Geisinger




**NEJM**  
Catalyst

**Medial**  
EarlySign





Colonoscopy Results Summer, 2019




## Results

- >8.8% PPV for Malignancies
- 33.5% for Polyps (11% high risk adenomas)
- Any kind of findings >42%
- <1% increase in colonoscopies
- Increased compliance to colonoscopy
- More than 70 ColonFlag associated cancer cases detected





# Workflow – Maccabi Workflow



\* - e.g. – under GI examination, Frail, After Bariatric Surgery, etc...


Property of Medial EarlySign. Confidential. Do not reproduce or distribute.




# MHS Polyp Prediction Tool

- Information Extraction:

- Age $\geq$ 45Y,
  - Colonoscopy reports free text (indication, findings)
  - Pathology reports free text
  - EMR- MHS database (diagnosis, lab)
  - MHS Family tree tool
- 
- 28,130 colonoscopies
  - AUC-0.66 >> 0.75



# Initial Implementation





# Conclusions

- Colonoscopy is on the rise and in need worldwide
- Medical and economical management
- Prioritization may be cardinal to prevent CRC related death
- Existing and novel prioritization tools should be explored along with sound, gradual implementation





- **MHS**  
**+Maccabitech**

Roni Romano

Ben Gadasi

Edna Bar-Ratzon

Nesia Gordon

Daniel Landsberger

Gabriel Hodik

Varda Shalev

Debbie Egger

# THANKS

- **Earlysign team**

Ori Geva

Eran Chomen

Nir Kalkstein

- **Stanford**  
**University**

Uri Ladabaum

